The peroxisome proliferator-activated receptor α-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain
Introduction
Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (mHS) is the key hepatic ketogenic enzyme responsible for initiating conversion of fatty acid-derived acetyl-CoA into the ketone bodies acetoacetate and β-hydroxybutyrate (Quant, 1994, Hegardt, 1999). Overexpression of mHS is associated with hepatic hyperketogenesis, with consequent lowered blood free fatty acids in transgenic mice expressing a P-enolpyruvate carboxykinase/mHS chimeric gene (Valera et al., 1994). Conversely, genetic mutations resulting in the absence of functional mHS result in profound hypoketonemia in humans (Bouchard et al., 2001). A critical component in the regulation of hepatic fatty acid oxidation and ketogenesis is the peroxisome proliferator-activated receptor alpha (PPARα) transcription factor. PPARα mediates fatty acid induction of mHS expression in rat (Rodriguez et al., 1994) and human (Hsu et al., 2001) hepatocyte-derived cell lines. In vivo, PPARα null mice exhibit profound alterations of hepatic lipid metabolism, especially during fasting (Leone et al., 1999) and, whereas fasting induces major increases in hepatic expression of mHS in PPARα +/+ mice with accompanying hyperketonemia, this effect is abolished in PPARα –/– mice (Le May et al., 2000). Furthermore, in addition to its role as a ketogenic enzyme, human mHS protein acts as a transcription factor co-activator of PPARα that synergistically activates expression of the mHS gene itself (Meertens et al., 1998). Together, such studies indicate that PPARα/mHS ‘systems’, at the genetic and enzymic levels, play a fundamental role in fatty acid homeostasis.
We have recently demonstrated PPARα expression in rat brain, and in primary cultures of rat cortical astrocytes (Cullingford et al., 1998a). Furthermore, we have demonstrated the, hitherto unsuspected, expression of mHS in rat brain (Cullingford et al., 1998b), shown that it is subject to developmental/dietary regulation (Cullingford et al., 1998b), and have further demonstrated its up-regulation by glucocorticoids in primary cultures of neonatal cortical astrocytes (Cullingford et al., 1998c). Based on our novel observations, we now wish to examine the pharmacological activation of brain PPARα/mHS ‘systems’ and hence the potential for in vivo manipulation of brain fatty acid oxidation and ketone body production. This has clinical implications in neuro-inflammatory disease since increased oxidative elimination of pro-inflammatory fatty acids is involved in PPARα-mediated protective action against the inflammatory response, atherosclerosis and aging (Pineda Torra et al., 1999). Furthermore, ketone bodies, the products of such fatty acid oxidation/ketogenesis, possess potential protective actions against epilepsy (Stafstrom, 1999), Alzheimer’s disease (Kashiwaya et al., 2000), Parkinsonism (Kashiwaya et al., 2000) and stroke (Dardzinski et al., 2000).
A range of fatty acids, hypolipidemic drugs and peroxisome proliferators can act as ligands for PPARα in vitro (Forman et al., 1997), some of which also have potent actions within the brain. Included in this category are the anti-hyperlipidemic drug ciprofibrate and the anti-epileptic drug valproate that are peroxisome proliferators in rodents (Keller et al., 1992). Ciprofibrate is a selective and potent PPARα ligand-activator in vitro (Forman et al., 1997, Takada et al., 2000). In vivo, ciprofibrate accesses brain of both neonatal and adult rats (Singh and Lazo, 1992), such that ex vivo brain homogenates derived from ciprofibrate-treated rats exhibit potently increased capacities to oxidize radiolabelled fatty acids (Singh and Lazo, 1992). The branch chain fatty acid valproate is apparently a pan-PPAR activator in vitro (Lampen et al., 1999, Gottlicher et al., 1998) that activates both PPARα and the two remaining receptor isoforms, PPARδ and PPARγ (Lampen et al., 1999, Gottlicher et al., 1998). The potent anti-epileptic action of valproate has likewise established it as a compound with a pharmacological action in brain (Löscher and Nau, 1985).
Thus, we have performed the sensitive and discriminatory RNase protection co-assay (Cullingford et al., 1998b) on brain total RNA derived from control- or drug-treated rats and monitored changes in mHS expression, via changes in mHS mRNA abundance, together with changes in two other hepatic PPARα-regulated genes, namely acyl-CoA oxidase (ACOX) (Marcus et al., 1993) and medium chain acyl-CoA dehydrogenase (MCAD) (Gulick et al., 1994). As a co-assay control, we have analyzed expression of acyl-CoA synthase 2 (ACS2), since it is regulated by another brain PPAR isoform, PPARδ (Basu-Modak et al., 1999). We have also examined liver as a control tissue, since it expresses PPARα at high levels (Cullingford et al., 1998a).
Section snippets
Ciprofibrate administration
Male weanling Wistar rats (Nihon Clea, Tokyo) of 30–40 g, individually housed, were fed ad libitum either a standard diet alone or one supplemented with 0.025% (w/v) ciprofibrate (Sigma), as previously described (Singh and Lazo, 1992), for 3 days. Water and food were provided ad libitum. Rate of consumption of the diet was similar in both groups and resulted in an intake of approximately 0.01 mmol/kg/day of ciprofibrate in the drug-treated group. No differences in weight gain were observed
Regulation of mHS, MCAD and ACOX mRNAs by ciprofibrate in liver and brain
Autoradiograms of RNase protection co-assays for mHS, ACS2, MCAD and ACOX mRNAs, using total RNA derived from livers and brains of control- or ciprofibrate-treated rats are illustrated in Fig. 1 and corresponding abundances of mRNAs are presented in Fig. 3A and B. In liver, ACS2 mRNA was beyond the limit of sensitivity of the RNase protection co-assay, whereas mHS, ACOX and MCAD were readily detected. Hepatic abundances of mHS, MCAD, and ACOX mRNAs exhibited increases of 3.3-, 2.8-, and
Discussion
Three PPAR isotypes have been identified in mammals, namely PPARα, γ, and δ (β) (Schoonjans, 1996). We (Cullingford et al., 1998a) and others (Basu-Modak et al., 1999) have identified mRNAs encoding all three PPAR isoforms in brain regions, reaggregated brain cell cultures, and primary cultures of astrocytes, with a general order of abundance: In this study, using RNase protection co-assay, we likewise find that the three PPAR mRNA isoforms are expressed in livers and brains
References (35)
- et al.
Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures
Journal of Biological Chemistry
(1999) - et al.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Analytical Biochemistry
(1987) - et al.
Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells
Journal of Biological Chemistry
(2001) - et al.
The human peroxisome proliferator-activated receptor PPAR subtype NUC1 represses the activation of hPPAR alpha and thyroid hormone receptors
Journal of Biological Chemistry
(1995) - et al.
Several nongenotoxic carcinogens uncouple mitochondrial oxidative phosphorylation
Biochimica et Biophysica Acta
(1992) - et al.
New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta)
Toxicolology and Applied Pharmacology
(1999) - et al.
Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression
FEBS Letters
(2000) - et al.
Pharmacological evaluation of various metabolites and analogues of valproic acid
Neuropharmacology
(1985) - et al.
Molecular cloning and nucleotide sequence of cDNA encoding the entire precursor of rat liver medium chain acyl coenzyme A dehydrogenase
Journal of Biological Chemistry
(1987) - et al.
Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids
Journal of Biological Chemistry
(1994)
The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation
Biochimica et Biophysica Acta
Peroxisomal enzyme activities in brain and liver of pups of lactating mothers treated with ciprofibrate
Neuroscience Letters
Animal models of the ketogenic diet: what have we learned, what can we learn?
Epilepsy Research
The effects of valproate on the arachidonic acid metabolism of rat brain microvessels and of platelets
European Journal of Pharmacology
Overexpression of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase in transgenic mice causes hepatic hyperketogenesis
Journal of Biological Chemistry
Mediators of injury in neurotrauma: intracellular signal transduction and gene expression
Journal of Neurotrauma
Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency: clinical course and description of causal mutations in two patients
Pediatric Research
Cited by (40)
HMG-CoA synthase 2 drives brain metabolic reprogramming in cocaine exposure
2019, NeuropharmacologyCitation Excerpt :Evidence has showed the alteration in brain ketogensis when subject is exposed to psychoactive drugs or participates in simple exercise/locomotor activity. However, fasting, high-fat or ketogenic diet increases HMGCS2 expression and triggers brain ketogenesis (Cullingford et al., 2002a, 2002b; König et al., 2008) without increasing locomotor activity (Kasprowska-Liśkiewicz et al., 2017; Ming et al., 2017; Ruskin et al., 2011; Thio et al., 2010). Notably, Hymeglusin (HMGCS2 inhibitor) decreases ventromedial hypothalamus ketones but cannot alter their food intake in high-fat diet rats (Le et al., 2014), which is consistent with the unchanged sucrose preference of mice receiving NAc-hymeglusin in our study (Fig.S3b).
Ketogenic response to cotreatment with bezafibrate and medium chain triacylglycerols in healthy humans
2015, NutritionCitation Excerpt :This difference, however, disappeared during the second 4 h of the metabolic study day such that the difference in overall 8 h AUC compared with CTL did not differ between the two treatments (+591 μM/h [MCT] versus +999 μM/h [BEZA+MCT]; P = 0.137). The aim of this study was to determine whether BEZA could improve the ketogenic effect of MCT in healthy adults via a presumed stimulation of PPARα and subsequent stimulation of the ketogenesis-limiting enzyme, HMG-CoA synthase [14]. We previously reported mildly increased ketogenesis and noted a correlation between the decrease in plasma TGs and the increase in β-OHB in hypertriacylglycerolemic patients while on BEZA alone [12].
Ketogenic diets, mitochondria, and neurological diseases
2014, Journal of Lipid ResearchCitation Excerpt :Activation of AMPK leads to the phosphorylation of multiple substrates, resulting in concurrent inhibition of anabolic pathways and increases in catabolic metabolism to enhance the production of ATP (136). These effects are known to include an upregulation of FAO and increased mitochondrial biogenesis (136). Similar to PPARs, agonists of AMPK are used to treat type II diabetes mellitus and metabolic syndrome (136).
Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: Application to acetaminophen injury
2012, Toxicology and Applied PharmacologyCitation Excerpt :In accordance with our previous work which showed that only small amounts of necrosis and apoptosis occurred in the biochips (Prot et al. 2011a), we found among the detected compounds in biochips when compared to plate cultures, a higher consumption of the histidine and methionine which are related to the Nrf-2 signaling and the glutathione metabolism, The fatty acid and lipid metabolism pathways were also highlighted by the profile integration via PPAR signaling, and butanoate and ketone metabolism (Fig. 3, Table 2) in coherence with numerous literature reports (Chapman, 2003; Cullingford et al., 2002). Steroids and cholesterol biosynthesis were also induced via the RXR and PXR pathways (Fig. 3, Table 2).